Antibiotic resistance in livestock: more at stake than steak. by Schmidt, Charles W
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I
magine, for a moment, this scenario: you, like millions of other people
around the world, are lying in a hospital bed suffering from a bacteri-
al infection. Your doctors have told you that your disease, which once
would have been easily treated, no longer responds to available drugs.
In addition to feeling shock and disbelief, you’d probably wonder how this
could have happened. 
You would not be alone. The specter of antibiotic resistance is considered
by many to be one of the most pressing scientific questions today. With
each passing year, former wonder drugs like penicillin, erythromycin, and
tetracycline are less effective against strains of treatment-resistant “super-
bugs.” By decreasing the number of effective drugs in the medical arsenal,
antibiotic resistance is making bacterial infections and related conditions
more difficult to treat. Scientists also worry that the spread of resistance
genes among even unrelated strains of bacteria could turn what are now
treatable illnesses into killers.
Where are these resistance traits coming from? Certainly overuse in
human medicine is an important source. But agricultural uses, particularlyin livestock, also contribute significantly
toward the problem of antibiotic resistance,
scientists say. 
As much as 70% of the antibiotics pro-
duced in the United States today (including
those approved but never or not currently
marketed) are for use in food animals,
according to the Union of Concerned
Scientists, a Cambridge, Massachusetts–
based organization of experts that advocates
for precautionary principles in environ-
mental debates. In addition to treating
disease, substantial amounts of these drugs
are given to healthy animals to prevent ill-
ness and to promote growth. Exactly why
antibiotics enhance weight gain is unclear.
Many experts believe they allow animals to
conserve energy that would otherwise be
devoted to fighting pathogens. But this
explanation isn’t universally accepted, and
the question is still debated. 
An Industry under Pressure
The pressure on agriculture to alter its use
of antibiotics has never been greater.
Earlier this year, in response to pressure
from environmental groups, the
McDonald’s, Wendy’s, and Popeyes fast-
food chains announced that they would no
longer buy chicken treated with an antibi-
otic called enrofloxacin because it’s related
to ciprofloxacin, a fluoroquinolone drug
used to treat Campylobacter—and
anthrax—in humans. The U.S. Food and
Drug Administration (FDA) is now with-
drawing approval for enrofloxacin (market-
ed as Baytril) from its producer, Bayer, due
to fluoroquinolone resistance
in strains of Campylobacter
that infect humans. (The
company refused to voluntar-
ily remove the drug from the
poultry market.) Three com-
panies—Tyson Foods, Perdue
Farms, and Foster Farms—
which combined produce a
third of the chickens raised in
the United States today,
announced last February that
they will no longer give
antibiotics to healthy birds.
And two bills in the
Congress, one authored by
Representative Sherrod
Brown (D–Ohio) and the
other by Senator Edward Kennedy
(D–Massachusetts), have proposed phasing
out uses of antibiotic formulations used in
both human and veterinary medicine in
healthy farm animals altogether. 
The Alliance for the Prudent Use of
Antibiotics (APUA), an advocacy group
based in Boston, Massachusetts, published
a report in the 1 June 2002 supplement to
Clinical Infectious Diseases culminating an
expert review of approximately 500 pub-
lished studies. The report calls for major
changes in antibiotic use. Echoing the
group’s conclusions, Sherwood Gorbach, a
professor of community medicine at Tufts
University Medical School in Boston and a
member of the APUA’s scientific advisory
board, says, “Nontherapeutic use of antibi-
otics in healthy animals for growth promo-
tion and feed efficiency should be discon-
tinued. Furthermore, certain antibiotics
that are critically important in human
medicine, such as fluoroquinolones and
third-generation cephalosporins, should
be restricted to use only in critically ill
animals and refractory cases under a vet-
erinarian’s prescription.” 
Some stakeholders insist these drastic
measures are unwarranted because antibiot-
ic use among people—not animals—is the
main cause of resistance to human antibi-
otics. They also question the degree to
which resistance genes in animal bacteria
are transferred to human bacteria. Data
addressing this question are just now being
collected, says Abigail Salyers, a professor of
microbiology at the University of Illinois at
Urbana-Champaign and president of the
American Society for Microbiology. What’s
needed, she explains, are more studies that
trace resistance genes back to agricultural
sources—something scientists are begin-
ning to explore. 
In  the meantime, industrial agricul-
ture has plenty of incentive to turn the
uncertainty to its advantage. Hanging in
the balance are billions in drug sales and
the future of industrial meat production,
which some argue can’t be sustained with-
out antibiotics at current use levels. All
across the United States, small farms are
giving way to huge consolidated feedlots
that facilitate the rapid spread of bacteria
and disease. Feedlots housing up to
100,000 cows within a few hundred acres
are not uncommon, according to
GeneNet, a Hays, Kansas–based livestock
marketing organization. In 1945, the typ-
ical henhouse contained 500 birds. Today,
the average ranges from 80,000 to
175,000. In 1980, there were 650,000
hog farms in the United States. In 2001,
there were 81,000, including Circle Four
Farms in Milford, Utah, a mega-facility
A 398 VOLUME 110 | NUMBER 7 | July 2002 • Environmental Health Perspectives
Focus •  More at Stake than Steak
t
o
p
 
t
o
 
b
o
t
t
o
m
:
 
U
S
D
A
;
 
P
h
o
t
o
D
i
s
c
No day at the spa. Some experts blame the increase in non-
therapeutic uses of antibiotics in animals, at least in part, for the
increasing resistance of microbes to antibiotics.
A shot in the dark? Researchers don’t really know how—and how much—the use of antibiotics
in animals may contribute to resistance in antibiotics that are also used in humans. Many say live-
stock breeders should err on the side of caution in antibiotic use until more is known.Environmental Health Perspectives • VOLUME 110 | NUMBER 7 | July 2002  A 399
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Healthy Animals, Unhealthy People? Popular Antibiotics on Farms and in Pharmacies
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✓ ✓ ✓housing 500,000 hogs in a 35-square-mile
area, according to the U.S. Department of
Agriculture (USDA). 
“If you take away the tools we have to
manage and control disease, we’ll have to
look for other alternatives,” says Ron
Phillips, a spokesperson for the Animal
Health Institute, a Washington,
D.C.–based trade group representing drug
companies that make antibiotics for the
food animal industry. “And to date, no one
has found an alternative that can match
antibiotics for disease control on the scale at
which we produce food today—at least not
one which allows consumers to buy meat at
such low prices.”
While no one disputes industry’s right
to treat sick animals with antibiotics, the
real issue, Salyers says, concerns industry’s
right to give antibiotics to healthy animals
for so-called nontherapeutic uses. And
what exactly are nontherapeutic uses? “The
answer to that question is the core of this
whole problem,” she says. “For example,
consider antibiotics used for prophylaxis,
meaning disease prevention. A farmer
might treat an entire flock or herd because
he believes there is a threat of disease, even
in the absence of sick animals. Is this ther-
apeutic? The industry would say it is. Most
activists would say it is not. Same for
growth promotion, which some industry
experts might consider to be prophylactic.
You could say antibiotics promote growth
because they limit infections. In this con-
text, growth promotion with antibiotics
can be said to be prophylactic. If you want-
ed to, you could even argue that all uses are
therapeutic.” 
This kind of semantics is where the pro-
posed changes in antibiotics-use policies get
hung up. In addition to restricting the use of
agricultural antibiotics that are also used in
humans, groups like the APUA want to
eliminate agricultural nontherapeutic uses,
particularly growth promotion. In response,
industry is striving to minimize the number
of defined nontherapeutic use categories. 
The Resistance Phenomenon
Antibiotic resistance has been a recognized
medical problem ever since the drugs
became widely available in the 1940s. With
each passing decade, emergent strains of
bacteria that defy not only single but also
multiple antibiotics have become increas-
ingly common. Some strains of human
pathogens, including Enterococcus faecalis,
Mycobacterium tuberculosis, and Pseudo-
monas aeruginosa, are now resistant to more
than 100 drugs. Meanwhile, diseases once
thought to be nearly eradicated—tuberculo-
sis, for instance—are making a troubling
return due to antibiotic resistance. 
Bacteria acquire resistance genes by
any of three routes: inheritance, sponta-
neous mutations
that produce new
resistance traits,
or acquisition of
genes from other
bacteria in their
vicinity in a process known as “horizontal
transfer,” or “bacterial sex.” Jokes Salyers,
“Evidence is mounting that your intestinal
tract is a swinging singles’ bar for bacteria.”
She adds, “And it’s all-inclusive. We’re talk-
ing about gene transfer across genus and
species lines. That’s like a human impreg-
nating a slug.” 
Evidence for horizontal transfer of
resistance genes from bacteria that infect
animals to those that infect humans is
beginning to emerge. In her own laboratory
studies, Salyers has found that the same
resistance gene exists in both enterococci of
animal origin and Bacteroides—the most
common bacteria in the human colon. The
smoking gun, she says, is in the gene’s DNA
sequence: the resistance genes have an iden-
tical genetic sequence even though the
genomes of the organisms themselves are
substantially different. 
The single greatest factor driving resist-
ance to a given antibiotic is simply use of
the drug. The more an antibiotic is used,
the more the bacteria become resistant to it.
For this reason, experts say, antibiotics
should be used sparingly, and at dose levels
intended to kill all or as many of the bacte-
ria causing an infection as possible. If too
little antibiotic is used (undertreatment),
the most susceptible
bacteria are killed off,
leaving a hardy group
of survivors that grow
and multiply into
resistant strains. 
Human abuse of
antibiotics in particu-
lar is a major public
health problem. Many
patients demand anti-
biotics routinely, and
just as many doctors
dispense antibiotics indiscrimi-
nately—often for viral infections
against which the drugs are useless.
And it’s not uncommon for
patients to stop taking antibiotics
as soon as they feel better, killing
only a fraction of the bacteria that
are making them sick. Antibiotic
use around the world is character-
ized by widespread chronic under-
treatment. 
Chronic undertreatment in
agriculture, particularly for non-
therapeutic uses no matter how
they are defined, is also endemic.
Regarding the extent of undertreat-
ment in the poultry industry,
Richard Lobb, a spokesperson for
the National Chicken Council, a
Washington, D.C.–based trade
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Murder most fowl? Bacteria such as Salmonella (inset) and Campylobacter, often associated with con-
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group, says, “Antibiotics for growth pro-
motion are given at very low levels: grams
per ton of feed. The compounds are used
to manage the gut flora of the bird, which
allows it to process feed more efficiently.”
According to Lobb, the dosage rate for
therapeutic use is “considerably higher,”
although the exact amount depends on the
specific drug.
Salyers says her own lab studies show
that long-term low-dose use patterns are by
far the most effective at selecting for resist-
ant bacteria. “These dosing regimens also
give the bacteria time to acquire genetic
changes that make them more fit,” she
adds. “Keep in mind that bacteria predate
plants and animals by billions of years, and
they are extremely adaptable. If they have
extra time to adapt, they will do so with
maximal efficiency. That’s why the low-dose
uses are such a concern.” 
The Human Health Risk from
Antibiotics in Animals
People are typically exposed to resistant
foodborne bacteria when they come into
contact with farm animals or when they eat
meat and meat products. Although many
types of foodborne bacteria cause human
illness, two are a key concern because they
infect so many people. Salmonella and
Campylobacter are each linked to millions of
cases of food poisoning annually, according
to the Centers for Disease Control and
Prevention (CDC). “These switch sides as
the number-one and number-two causes of
bacterial foodborne disease in the United
States,” says Lyle Vogel, who heads the
Scientific Activities Division at the
American Veterinary Medical Association.
The effects caused by either organism range
from barely noticeable, to uncomfortable,
to fatal in rare cases involving infants, the
elderly, or people with compromised
immune systems.
Resistant strains of these bacteria have
been emerging with some frequency. For
example, in 1999, scientists at the CDC
began tracking a new variety of Salmonella
called Newport 9+, which is named for its
unprecedented resistance to nine antibiotics
including ceftriaxone, one of the few drugs
that kills most bacteria and the drug of
choice for children whose Salmonella infec-
tions enter the bloodstream (a condition that
kills about 1,000 Americans every year). 
The National Antimicrobial Resistance
Monitoring System (NARMS) surveillance
mechanism, which is coordinated by the
FDA, the CDC, and the USDA, provides
data that allow researchers to correlate
trends in animal antibiotic use to resistance
in human pathogens. Currently, NARMS
collects data on Salmonella, Escherichia coli
O157, Campylobacter, and Shigella and their
susceptibility to 17 antimicrobial drugs.
Results can be compared with data from
previous years to look for changes in the
resistance of the organisms to these drugs.
According to data collected by NARMS,
12% of all Salmonella isolates obtained from
human clinical samples in 2000 were resist-
ant to at least five antibiotics, including
ampicillin, chloramphenicol, streptomycin,
sulfamethoxazole, and tetracycline. All of
these drugs or the classes of drugs they
belong to are used in agriculture. In 1996,
the year NARMS began gathering data,
only 6% of human Salmonella isolates
showed this resistance pattern.
Furthermore, a series of studies published in
the 18 October 2001 issue of the New
England Journal of Medicine showed high
levels of resistant foodborne pathogens in
supermarket chicken. 
While untreatable food poisoning can
make someone very sick, an even more
serious problem can result if resistant
strains of enteric bugs escape the digestive
tract and infect other parts of the body.
The most likely scenario for this to happen
is during surgery. Says Salyers, “If your
bowels are accidentally perforated such
that intestinal bacteria get into the blood-
stream, the chance of developing a hard-to-
treat postsurgical infection is greatly
increased.” 
Stuart Levy, a professor of molecular
biology, microbiology, and medicine at
Tufts University Medical School and presi-
dent of the APUA, adds that the flow of
resistance genes is hardly limited to food-
borne pathogenic bacteria. As members of
a microbial ecosystem, any bacterium—
even a benign strain—could acquire a
resistance gene and pass it on to its neigh-
bors, including the dangerous bugs that
cause pneumonia, urinary tract infections,
and sexually transmitted diseases. Thus, a
resistance gene that starts out in an animal
strain of Salmonella typhimurium could
end up in Klebsiella pneumoniae (a cause of
human pneumonia); similarly, a resistance
gene in an animal strain of Enterococcus
faecium could end up in Staphylococcus
aureus, which causes intractable hospital-
based infection resistant to nearly 100
drugs. “It would be hard to trace an
untreatable urinary tract infection to
antibiotic use on a farm,” Levy says. “But
it’s nevertheless possible that farm use
could be the source of the resistance.” 
A Dwindling Arsenal
A troubling parallel to the problem of
resistance is the lack of new effective antibi-
otics—the pipeline for fresh drugs has been
running low for years. The goal for public
health is therefore to retain the usefulness of
as many existing antibiotics as possible.
Those used purely in animals—such as
ionophores, which improve feed efficiency
in sheep and cattle but are too toxic for use
in people—are of little concern. The antibi-
otics experts worry about most are those
that are used in both animals and people:
mainly tetracycline, fluoroquinolones,
third-generation cephalosporins, and
macrolides, according to Vogel. 
Lately, to industry’s dismay, activists
have targeted a drug called virginiamycin
that has been used in animals, mainly poul-
try, for 25 years. Virginiamycin is related to
a new human drug called Synercid, which
is an emerging replacement for one of the
most valuable antibiotics in the clinician’s
arsenal, vancomycin. Practitioners were
shocked when vancomycin-resistant strains
of E. faecium began to emerge in the late
1990s. The source of at least some van-
comycin resistance in E. faecium was traced
back to a related antibiotic called
avoparcin—never approved for use in the
United States—which was used for growth
promotion in the European poultry indus-
try. These uses have since been discontin-
ued. Activists worry that a similar scenario
may play out for virginiamycin.
To date, regulatory action to remove an
animal antibiotic because of a human resist-
ance threat is limited to the FDA’s offensive
against fluoroquinolones in the poultry
industry, but the FDA is conducting a risk
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Draining the supply. In addition to use in
animals, the overuse of antibiotics in humans
is considered a major factor in the reduction of
the number of effective antibiotics. assessment of virginiamycin use. Industry
watchers say Baytril withdrawal isn’t likely
to happen anytime soon—stakeholders say
the FDA’s campaign against Bayer could
take anywhere from 10 to 20 years. In fact,
some critics complain that the FDA’s hands
are inadvertently tied by a multilayered set
of hearings and appeals. “The agency does-
n’t have an effective way to deal with this
kind of problem,” says Tamar Barlam,
director of the Antibiotic Resistance Project
at the Center for Science in the Public
Interest, a Washington, D.C.–based advo-
cacy group. “The only practical solutions
are voluntary industry withdrawals or legis-
lation that bans sale of the drug.” 
Both the Kennedy and Brown bills pro-
pose to ban the use of ciprofloxacin-like
antibiotics to treat sick poultry. In addition,
both bills would ban the use of eight
human antibiotics in feed animals within
two years of enactment unless the FDA
determines that these uses don’t contribute
to antibiotic resistance problems. 
In recent years, the FDA has revamped
its new drug approval process for animal
antibiotics, specifically targeting potential
human resistance problems as a safety end
point. As part of this new approach, says
Stephen Sundlof, director of the FDA’s
Center for Veterinary Medicine, the agency
is asking drug companies for better infor-
mation about resistance implications. “But
this is difficult to evaluate,” Sundlof says.
“We can’t really predict when and if resist-
ance will happen and at what rate. If you
assume the worst you’ll never approve
another drug, and if you’re too lenient
you’re not doing your job either. So we’re
using a risk-based process that takes into
account the importance of the drug in
human medicine.” 
The Future for Food Safety and
Production
So what happens if antibiotic use in animals
is reduced or eliminated? The European
experience provides one perspective on the
implications of reducing food animal
antibiotics. Since 1999, the European
Commission has tightly regulated animal
antibiotics related to those used in human
medicine. The leader in these efforts is
Denmark, which reduced its animal use of
antibiotics by roughly 60% from 1994 to
2000. 
According to a 27 March 2002 article in
The Washington Post, the use of growth-pro-
moting antibiotics in Denmark has fallen to
zero from a 1994 peak of 128 tons. In the
article, Henrik C. Wegener, a researcher
with the Danish Veterinary Institute in
Copenhagen, is quoted as saying the
Danish ban has markedly decreased the
prevalence of drug-resistant bacteria but has
not affected the health of the animals or the
price of meat. Wegener does acknowledge
that more feed is required to maintain ani-
mal weight, but these costs are balanced by
the savings in drug costs. 
However, Vogel, who represents the vet-
erinary profession on matters related to
antibiotics, is skeptical of the Danish claims.
Denmark also reports a 30% increase in the
use of antimicrobials to treat diseases in
2000, he says. “Until the illnesses are
resolved, the health and welfare of the ani-
mals are clearly impacted.” 
Ultimately, the issue of agricultural
antibiotic use and resistance boils down to
familiar questions in public health: should
precautionary measures be taken to mini-
mize a threat that isn’t well characterized, or
should we wait until more data are available
before taking conclusive actions? Just as care
providers and patients alike have a role to
play in conserving antibiotics, so do farmers
and drug companies. But controlling the
spread of resistance won’t come without a
certain degree of economic pain and, poten-
tially, a detrimental effect on animal health
and welfare. “If you want cheap meat from
cows that are confined to a small number of
locations rather than wandering in the sub-
urbs and parks, then you have to face the
consequences of that desire,” says Salyers.
“One of those consequences is massive use
of antibiotics.” 
Reducing antibiotic inputs will require
changes in animal husbandry that promote
hygiene and minimize the spread of bacte-
ria. Just how the U.S. food animal industry
will accommodate these changes is unclear.
“Farmers are going to need help,” Salyers
says. “We can’t get them addicted to antibi-
otics and then just tell them to quit cold
turkey. We need to have some respect for
their problems. If we’re going to move to
reduce antibiotics in agriculture, we’re
going to have to work with agriculture on
making that transition.” 
Charles W. Schmidt
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The economic equation. Livestock breeders say that reducing the use of antibiotics in ani-
mals will significantly impact the cost of meat, though environmentalists and others say the
cost of antibiotic resistance would be far greater.